Actuate Therapeutics offers asymmetric upside from elraglusib’s Phase 2-validated pancreatic-cancer signal, but near-term survival depends on financing, severe dilution and Nasdaq compliance.
Actuate Therapeutics, Inc. (NASDAQ: ACTU) is a clinical-stage biopharmaceutical enterprise focused on the development and commercialization of targeted small-molecule therapeutics for high-impact, difficult-to-treat cancers and severe inflammatory diseases [cite: 1, 2]. Founded in 2015, the company's research and operational priorities center on advancing its proprietary lead candidate, elraglusib (9-ING-41) [cite: 1, 2]. Elraglusib is a first-in-class, highly selective inhibitor of glycogen synthase kinase-3 beta (GSK-3β), an enzyme that regulates key pathways in cancer cell survival, chemoresistance, nuclear factor kappa B (NF-kB) transcriptional activity, and tumor-mediated immune evasion [cite: 2, 3].
As a clinical-stage development entity, Actuate generates zero commercial product revenue [cite: 4, 5]. Operations and clinical development programs are entirely capitalized through public equity offerings, private placements, and committed equity funding facilities [cite: 6, 7]. The company operates within the global oncology pharmaceuticals market, targeting patient populations with significant unmet clinical needs [cite: 1, 2]. Actuate's primary target markets comprise first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), recurrent or metastatic salivary gland carcinoma (SGC), pediatric neuroblastoma, advanced melanoma, colorectal cancer, and RAS-mutant solid tumors [cite: 1, 6, 7, 8].
The ultimate customer ecosystem for Actuate’s therapeutic pipeline includes institutional healthcare providers, specialized comprehensive cancer centers, hospital networks, and potential biopharmaceutical licensing partners [cite: 4, 8]. Clinicians and researchers choose elraglusib over existing therapeutic alternatives due to its multimodal mechanism of action [cite: 2, 8]. Unlike conventional cytotoxic therapies that often induce systemic toxicity without overcoming drug resistance, elraglusib downregulates pro-survival genes, restores sensitivity to standard chemotherapy, and stimulates anti-tumor immune responses by promoting intratumoral infiltration of CD8+ T cells and granzyme-B+ cytotoxic cells [cite: 2, 9]. In randomized Phase 2 clinical trials, elraglusib combined with standard gemcitabine/nab-paclitaxel chemotherapy produced statistically significant improvements in overall survival among first-line mPDAC patients without exacerbating systemic safety issues [cite: 7, 9].
Actuate Therapeutics functions as a single-asset biopharmaceutical developer [cite: 1, 2]. Evaluating the strategic value of ACTU requires examining its therapeutic candidate, intellectual property estate, addressable market dynamics, and competitive positioning within gastrointestinal and rare oncology markets [cite: 4, 7, 8].
Actuate is advancing elraglusib across two primary delivery formulations: an intravenous (IV) solution and an oral tablet formulation [cite: 6, 7].
| Formulation | Current Development Stage | Primary Target Indications | Core Strategic Objective |
|---|---|---|---|
| Elraglusib IV | Phase 2 Completed / Phase 3 Planning | 1L Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC); Salivary Gland Carcinoma; Pediatric Neuroblastoma | Demonstrate superior overall survival and chemosensitization in combination with standard chemotherapy regimens (Gemcitabine / nab-Paclitaxel) [cite: 6, 7]. |
| Oral Elraglusib | Phase 1/2 (FDA IND Cleared) | Advanced Solid Tumors; RAS-driven Cancers | Provide flexible outpatient maintenance dosing and enable combination regimens with oral targeted agents (e.g., RAS inhibitors) [cite: 1, 6, 10]. |
The primary value driver across Actuate's portfolio is the randomized Phase 2 trial (Actuate-1801 Part 3B) evaluating IV elraglusib in 286 patients with previously untreated mPDAC [cite: 7]. The study met its primary efficacy endpoint, demonstrating that adding elraglusib to standard gemcitabine/nab-paclitaxel (GnP) extended median overall survival (mOS) to 10.1 months compared to 7.2 months for GnP alone (Hazard Ratio = 0.62, p = 0.02) [cite: 7]. Furthermore, the study recorded a near-doubling of 12-month overall survival rates (44.4% for elraglusib/GnP vs. 22.3% for control) and an almost fivefold increase in 24-month survival rates (12.9% vs. 2.6%), highlighting long-term clinical durability [cite: 7].
Actuate's pipeline architecture spans several developmental stages:
Actuate’s economic protection relies on regulatory exclusivity and a global intellectual property estate [cite: 8, 11]:
Actuate's primary market opportunity is driven by pancreatic cancer, with expansion opportunities into secondary oncology settings [cite: 4, 8]:
The first-line therapeutic landscape for mPDAC is dominated by cytotoxic chemotherapy combinations, primarily Gemcitabine plus nab-Paclitaxel (GnP) and multi-agent irinotecan regimens like modified FOLFIRINOX / NALIRIFOX [cite: 6, 7].
| Regimen / Candidate | Sponsor / Class | Benchmark Efficacy (mOS) | Actuate Positioning & Advantage |
|---|---|---|---|
| Gemcitabine + nab-Paclitaxel (GnP) | Generic / Standard Cytotoxic | 6.7 – 7.2 months | Elraglusib acts as an additive chemosensitizer, raising mOS to 10.1 months without adding systemic toxicity [cite: 7, 9]. |
| NALIRIFOX / FOLFIRINOX | Ipsen / Cytotoxic Combination | ~11.1 months | High systemic toxicity limits usage in fragile patients; Elraglusib/GnP offers comparable survival with a better safety profile [cite: 7, 9]. |
| RMC-6236 (RAS Multi-Inhibitor) | Revolution Medicines / Targeted | Early Clinical Stage | Synergistic combination partner; Actuate is evaluating oral elraglusib with RAS inhibitors to block bypass resistance pathways [cite: 1, 10]. |
Actuate positioning relies on targeting GSK-3β to reverse chemoresistance and enhance anti-tumor immunity, establishing elraglusib as a potential combination partner for standard chemotherapies rather than a direct replacement [cite: 2, 7, 9].
Actuate Therapeutics reported its condensed consolidated financial results for the second quarter ended June 30, 2026 (Q2 2026) via Form 10-Q filed with the SEC on August 14, 2026 [cite: 6, 12]. Top-line revenue remained at $0, consistent with its pre-commercial development status [cite: 4, 5].
| Financial Line Item | Q2 2026 (3 Months Ended Jun 30, 2026) | Q2 2025 (3 Months Ended Jun 30, 2025) | Six Months Ended Jun 30, 2026 | Six Months Ended Jun 30, 2025 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Research & Development (R&D) | $2,066,825 | $2,764,805 | $4,632,069 | $5,985,124 |
| General & Administrative (G&A) | $2,839,763 | $3,204,072 | $5,980,475 | $6,349,337 |
| Total Operating Expenses | $4,906,588 | $5,968,877 | $10,612,544 | $12,334,461 |
| Net Loss | $(4,866,635) | $(5,949,405) | $(10,492,384) | $(12,266,429) |
| Basic & Diluted Loss Per Share | $(0.20) | $(0.30) | $(0.44) | $(0.63) |
| Weighted Shares Outstanding | 24,013,577 | 19,572,564 | 23,705,417 | 19,572,564 |
Operating losses narrowed year-over-year in Q2 2026, primarily due to a $0.70 million decrease in R&D expenses [cite: 12]. External clinical study expenditures fell by $0.75 million (from $1.52 million in Q2 2025 to $0.77 million in Q2 2026) as patient enrollment in the Phase 2 mPDAC trial (Actuate-1801 Part 3B) concluded, lowering CRO and site operational costs [cite: 12]. This reduction was partially offset by a $0.17 million increase in R&D personnel and consulting costs (reaching $1.03 million) driven by stock-based compensation and regulatory filings support [cite: 12]. General and administrative expenses declined by $0.36 million, reflecting lower annual performance bonus accruals and reduced corporate insurance premiums [cite: 12].
As of June 30, 2026, Actuate held cash and cash equivalents of $4,425,841 and working capital of $942,745, down from $13,159,423 in cash at December 31, 2025 [cite: 6, 7, 12]. Total assets stood at $5,199,339 against total liabilities of $4,210,136 (including $1.94 million in accrued clinical trial costs), yielding stockholders' equity of $989,203 [cite: 9, 12]. The company carries zero long-term debt [cite: 9].
Management disclosed in the Form 10-Q filing that existing cash reserves were insufficient to fund operations past September 2026, leading to a substantial doubt regarding the company's ability to continue as a going concern [cite: 6, 12].
To address its liquidity position, Actuate filed a Form S-1 registration statement on October 6, 2026, proposing a primary follow-on offering of 50,000,000 shares of common stock at an assumed public price of $0.819 per share (the last reported sale price on October 2, 2026) [cite: 7]. The filing included a 45-day over-allotment option for up to 7,500,000 additional shares and warrants for 3,700,000 shares exercisable at 150% of the public offering price [cite: 7].
This offering significantly expands the share count, increasing outstanding common stock from 24,013,577 shares (as of June 30, 2026) to over 74,013,577 shares, diluting existing equity holders by more than 200% [cite: 7, 12].
Because Actuate is pre-revenue, sell-side earnings evaluations focus on clinical timelines and liquidity management [cite: 5, 13]. Following Q2 2026 going-concern disclosures and equity dilution filings, Wall Street analysts adjusted price targets while maintaining buy ratings based on elraglusib's clinical trial results [cite: 5, 14]:
The mean analyst price target stands between $9.20 and $11.68 [cite: 5, 16]. Equity offerings at $0.819 per share have contributed to a 90% stock price decline from Actuate's August 2024 IPO price of $8.00 per share [cite: 2, 4, 7].
| Metric | Baseline Value (October 2026) | Sector Benchmark | Operational Context & Valuation Driver |
|---|---|---|---|
| Share Price | $0.819 USD | N/A | Trades near the low end of its 52-week range ($0.60 – $8.49) [cite: 7, 15]. |
| Market Capitalization | ~$19.67 Million | $850 Million (Biotech) | Reflects a distressed valuation driven by dilution overhang [cite: 4]. |
| Enterprise Value (EV) | ~$15.25 Million | N/A | Calculated as Market Cap minus $4.43M cash [cite: 4, 12]. |
| Price-to-Sales (P/S) | N/A | 4.1x | Pre-revenue status [cite: 4]. |
| Price-to-Book (P/B) | ~19.8x | 2.5x | Elevated due to book value reduction from accumulated net losses [cite: 4, 12]. |
The market valuation reflects a heavy discount tied to dilution and financing risks rather than the drug's potential value [cite: 5, 6, 7]. Long-term valuation depends on Phase 3 trial execution in mPDAC, commercial launch timing (2028–2029), Phase 3 approval probabilities (typically 35–45% in oncology), and share count stabilization post-offering.
Evaluating Actuate Therapeutics requires assessing clinical execution, balance sheet constraints, regulatory conditions, and capital market trends [cite: 6, 7, 12].
Actuate operates as a single-asset clinical biopharmaceutical developer [cite: 1, 2]. Its valuation depends almost entirely on the successful clinical development and regulatory approval of elraglusib [cite: 2, 6]. If Phase 3 clinical trials fail to achieve statistically significant overall survival endpoints, or if unexpected toxicities emerge in oral formulation studies, the company lacks secondary clinical assets to support its pipeline valuation [cite: 6, 7].
The company's primary operational risk is its limited cash runway [cite: 6]. With quarterly operating cash burn running between $4.5 million and $5.0 million and cash reserves at $4.43 million as of June 30, 2026, Actuate requires ongoing equity financing [cite: 6, 7, 12]. The 50 million share offering registered in October 2026 dilutes existing equity holders [cite: 7]. If capital markets restrict further share issuances, management may be forced to delay clinical trials, license candidate rights under unfavorable terms, or cease operations [cite: 6, 12].
Actuate was notified by Nasdaq that it failed to maintain the $50 million minimum market value of listed securities required for continued listing during the 30 business days ended July 14, 2026 [cite: 7]. Nasdaq granted the company until January 11, 2027, to regain compliance [cite: 7]. Failure to achieve a $50 million market value or maintain a $1.00 minimum bid price could result in delisting to over-the-counter (OTC) markets, reducing institutional liquidity and capital access [cite: 7, 17].
The oncology landscape remains highly competitive [cite: 2, 7]. Established pharmaceutical companies with greater financial resources are advancing alternative candidates for mPDAC and RAS-driven malignancies, including multi-RAS inhibitors, selective KRAS inhibitors, cellular therapies, and bispecific antibodies [cite: 1, 10, 14]. Clinical breakthroughs by competitors could shift standard-of-care guidelines and limit market opportunity for elraglusib [cite: 7].
Biotechnology equity markets remain sensitive to interest rate environments and risk sentiment [cite: 6, 18]. Higher interest rates reduce risk appetite for non-revenue biotech assets, increasing dilution during capital raises [cite: 6, 18]. Additionally, U.S. healthcare policy updates under the Inflation Reduction Act (IRA) could impact long-term net pricing dynamics for novel oncology drugs [cite: 18].
The 5-year valuation model evaluates Actuate Therapeutics through FY 2031 [cite: 4, 7]. The baseline share price is $0.819 USD (reflecting the SEC Form S-1 baseline price of October 2, 2026) [cite: 7]. The baseline share count assumes execution of the 50 million share primary offering, expanding basic shares outstanding to 74.0 million [cite: 7, 12].
| Scenario | Revenue / key scale metric in Year 5 | Margin / earnings assumption | Valuation multiple assumption | Current share price | Implied future share price | 5-year total return | Annualized return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | $520.0 Million USD | 32.0% Net Margin ($166.4M Net Income) | 22.0x P/E | $0.819 USD | $38.53 USD | +4,604.5% | +115.8% | 0.20 |
| Base Case | $220.0 Million USD | 25.0% Net Margin ($55.0M Net Income) | 18.0x P/E | $0.819 USD | $9.00 USD | +998.9% | +61.5% | 0.35 |
| Low Case | $0.0 Million USD | N/A (Operating Loss / Liquidation) | 0.0x P/E | $0.819 USD | $0.05 USD | -93.9% | -45.1% | 0.45 |
$\text{Weighted Price Target} = (0.20 \times \$38.53) + (0.35 \times \$9.00) + (0.45 \times \$0.05)$
$\text{Weighted Price Target} = \$7.706 + \$3.150 + \$0.0225 = \mathbf{\$10.88\text{ USD}}$
The probability-weighted target price of $10.88 USD demonstrates that despite a 45% probability of capital loss, potential upside from Phase 3 success in mPDAC generates an asymmetrical return profile relative to the baseline $0.819 share price [cite: 5, 6, 7].
HIGHLY SPECULATIVE PROFILE.
Blended Qualitative Score: 4.1 / 10
BINARY RISK PROFILE.
Actuate Therapeutics (ACTU) presents a binary investment profile, combining validated Phase 2 clinical efficacy with ongoing balance sheet and dilution challenges [cite: 2, 6, 7].
The strategic thesis rests on three core elements:
Actuate Therapeutics functions as a long-term option on the Phase 3 clinical outcome of elraglusib [cite: 6, 7]. If the company executes its equity financing, maintains its exchange listing, and advances elraglusib through pivotal Phase 3 trials, the asset holds potential for fundamental re-rating [cite: 5, 7]. Conversely, if financing access narrows or clinical trials falter, capital loss remains a risk [cite: 6, 7, 12].
HIGHLY SPECULATIVE ASSET.
Actuate Therapeutics trades in a long-term technical downtrend, driven by persistent equity dilution overhang [cite: 4, 7]. Trading near $0.82 USD, the stock remains well below its 200-day simple moving average (SMA), having declined approximately 90% from its August 2024 IPO price of $8.00 USD [cite: 2, 4, 7]. Technical momentum indicators show oversold conditions, but short-term price action remains constrained by the 50 million share primary offering registered in October 2026 [cite: 7]. Near-term share movement will depend on offering execution, market value progress ahead of the January 11, 2027 Nasdaq compliance deadline, and clinical protocol updates for pivotal Phase 3 mPDAC trials [cite: 7, 8].
BEARISH SHORT-TERM TREND.
View Actuate Therapeutics, Inc. Common stock (ACTU) stock page
Loading the interactive version of this report…